Health-related quality of life in undergraduate women using any contraceptive.

OBJECTIVE: The aim of this research was to assess university students' health-related quality of life whether they use some contraceptive method or not. METHODS: This research is a cross-sectional study. Female participants who studied a degree in health at the University of Seville (Spain) were recruited. Respondents completed a demographic questionnaire and health-related quality of life was measured with validated instrument SEC-QoL (Sociedad Española de Contracepción- Quality of Life) in Spanish that measured five dimensions: sexual, social, breast, menstrual and psychosocial. RESULTS: A total of 992 women aged 21.37 (3.6) years old participated in this study. Women who used a contraceptive method reached higher scores at the SEC-QoL questionnaire 47.09 (17.04) and 46.91 (18.73) than those that didn't. Likewise, women who chose a hormonal method showed a better overall health-related quality of life, compared to those who used a non-hormonal method. Participants who used hormonal contraceptives obtained higher scores in all health-related quality of life domains (social, menstrual, breast and sexual), except psychological domain when compared to those who used a non hormonal method or none. Furthermore, a moderated mediation model showed that the effect of the current contraceptive method on health-related quality of life was partially explained by the moderated mediation of the time using this method, the reason for using it and the existence of a partner. CONCLUSION: The usage of hormonal contraceptives increases health-related quality of life in young women. Several variables regarding the experience with contraceptive methods should be considered in order to examine the effect on health-related quality of life in undergraduate women.

Safety and patients' satisfaction after hysteroscopic sterilisation.

The aim of this study was to understand the potential complications of the Essure® device as well as the factors influencing its onset and patient satisfaction. We present a 9-year descriptive prospective study that included 1068 patients. The device was placed in 1056 of them (98.8%); 894 had no pain or mild pain during the insertion and only 12 patients experienced pain greater than menstrual pain. The proportion of patients without pain was greater in the group that took NSAIDs or NSAIDs and BZD and the unmedicated group had the highest rate of severe pain (p = .00). In all, 161 of the 1064 patients who had the Essure® inserted reported having an adverse effect during the 3-months post-insertion (pelvic pain or discomfort). The mean score out of 10 attributed to this method was 9.06 (S = 1.11). We concluded that the Essure® shows a low rate of complications and users showed a high degree of satisfaction. Impact statement What is already known on this subject: There are few international publications on Essure®. When we conducted a search in PubMed for the term 'Essure', we obtained 221 publications. When we added the terms 'Essure and complications', we obtained 20 publications, and when we increased the restriction including 'satisfaction', we obtained seven; thus, the uniqueness of our study. What the results of this study add: We present a 9-year descriptive prospective study that included 1068 patients. The aim of this study was to understand the potential complications of the Essure® device (Bayer, Whippany, NJ), as well as factors that can influence its onset and the patient satisfaction. The device was placed in 1056 of the patients (98.8%); 894 had no pain or mild pain during the insertion and only 12 patients experienced pain greater than menstrual pain. The proportion of patients without pain was greater in the group that took NSAIDs or NSAIDs and BZD and the unmedicated group had the highest rate of severe pain (p=.00). What the implications are of these findings for clinical practice and/or further research: Our study shows a low rate of complications with Essure®, mild and transient in most cases, as well as a high degree satisfaction. Nevertheless, given the few published studies on this device, we believe that long-term follow-up is needed.

Mastectomía por fibroadenoma gigante localmente avanzado / Mastectomy for locally advanced giant fibroadenoma

El fibroadenoma es el tumor mamario benigno más frecuente en las mujeres entre los 20 y 35 años. Hay diferentes variantes, destacando el fibroadenoma gigante sobre el cual presentamos el caso clínico. El fibroadenoma gigante ha sido definido como un fibroadenoma cuyo diámetro máximo es mayor de 5 cm o que pesa más de 500 g. El diagnóstico inicial se basa en la historia clínica y en la examinación física, y el diagnóstico definitivo se realiza mediante el estudio histológico. El tratamiento quirúrgico debe de ser valorado individualmente, optando por la resección en casos de crecimiento muy rápido y casos muy sintomáticos. En los casos en los que existe una asimetría mamaria severa, se podría emplear la técnica de «T» invertida, que es eficaz en la reducción del volumen y la corrección de la ptosis en hipertrofia mamaria, e incluso plantear la mastectomía (AU)

Fibroadenoma is the most common benign breast tumor in women aged between 20 and 35 years. There are different variants, including giant fibroadenoma. We report a case of this entity. Giant fibroadenoma has been defined as a fibroadenoma with a maximum diameter larger than 5 cm or weighing more than 500 g. The initial diagnosis is based on clinical history and physical examination and definitive diagnosis is made by histological analysis. Surgical treatment should be individually assessed and resection is recommended in patients with fibroadenomas with very rapid growth and in highly symptomatic patients. In patients with severe mammary asymmetry, the inverted «T» technique can be used, which is effective in reducing the volume and correcting ptosis in breast hypertrophy. Mastectomy is also an option (AU)